The estimated Net Worth of Benjamin L Palleiko is at least 4.41 百万$ dollars as of 6 September 2024. Mr. Palleiko owns over 15,625 units of KalVista Pharmaceuticals Inc stock worth over 2,767,389$ and over the last 8 years he sold KALV stock worth over 613,234$. In addition, he makes 1,028,480$ as Chief Financial Officer、 Chief Business Officer at KalVista Pharmaceuticals Inc.
Benjamin has made over 15 trades of the KalVista Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,625 units of KALV stock worth 167,500$ on 6 September 2024.
The largest trade he's ever made was exercising 51,031 units of KalVista Pharmaceuticals Inc stock on 17 May 2024 worth over 547,052$. On average, Benjamin trades about 11,478 units every 70 days since 2016. As of 6 September 2024 he still owns at least 258,152 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Mr. Palleiko stock trades at the bottom of the page.
Benjamin L. Palleiko serves as Chief Financial Officer, Chief Business Officer of the Company. Mr. Palleiko joined as Chief Financial Officer of KalVista Limited in August 2016 and was appointed as our Chief Financial Officer in November 2016. Mr. Palleiko was appointed as our Chief Business Officer in addition to his role as Chief Financial Officer in March 2019. Prior to joining us, Mr. Palleiko was co-Founder and CEO of Cielo Therapeutics, Inc. from 2012 until June 2016. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko was an investment banker with the firms Robertson Stephens and SunTrust Bank. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. He served as a Naval Aviator in the U.S. Navy.
As the Chief Financial Officer、 Chief Business Officer of KalVista Pharmaceuticals Inc, the total compensation of Benjamin Palleiko at KalVista Pharmaceuticals Inc is 1,028,480$. There are 2 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of 1,731,160$.
Benjamin Palleiko is 54, he's been the Chief Financial Officer、 Chief Business Officer of KalVista Pharmaceuticals Inc since 2019. There are 11 older and 6 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.
Benjamin's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over 74,823,944$ worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth 58,591,487$ . The most active insiders traders include Holdings A/S Novo、Capital Management, L.P.Ra ...、Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of 835,088$. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth 167,500$.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: